| Literature DB >> 35572168 |
Yuchen Ma1,2, Le Cui1,2, Yan Tian3, Congfen He1,2.
Abstract
Background and Aims: Self-perception of sensitive skin (SPSS) has several consequences, including skin barrier damage, which is prevented by barrier sebum. We analyzed lipidome profiles of skin surface lipids (SSLs) in patients with SPSS and healthy controls and explored the mechanism of action of potential lipid markers on the repair of damaged barrier cells to better understand SSL abnormity in these patients.Entities:
Keywords: lipidomics; skin barrier; skin sensitivity; skin surface lipid; ultraperformance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry
Year: 2022 PMID: 35572168 PMCID: PMC9075607 DOI: 10.1002/hsr2.632
Source DB: PubMed Journal: Health Sci Rep ISSN: 2398-8835
Reverse‐transcription polymerase chain reaction primer sequences
| No. | Protein name | Primer sequence |
|---|---|---|
| 1 | SREBP‐1c | 5’‐GGAGCCATGGATTGCACTTT‐3’ |
| 5’‐TCAAATAGGCCAGGGAAGTCA‐3’ | ||
| 2 | FFA | 5’‐CAGGCACACACGATGGAC‐3’ |
| 5’‐CGGAGTGAATCTGGGTTGAT‐3’ | ||
| 3 | SCD | 5’‐CCGGGAGAATATCCTGGTTT‐3’ |
| 5’‐GCGGTACTCACTGGCAGAGT‐3’ | ||
| 4 | PPARα | 5’‐GCGAACGATTCGACTCAAGC‐3’ |
| 5’‐CATCCCGACAGAAAGGCACT‐3’ | ||
| 5 | PPARβ | 5’‐CACCAACGAGACCTCTCCCG‐3’ |
| 5’‐ACCCCTCACATGCATGAACA‐3’ | ||
| 6 | PPARγ | 5’‐TGGAATTAGATGACAGCGACTTGG‐3’ |
| 5’‐AGGACTCAGGGTGGTTCAGC‐3’ | ||
| 7 | GCase | 5’‐ACATGACCCATCCACATCGG‐3’ |
| 5’‐GAGAAGACCACAGGGGTTCC‐3’ | ||
| 8 | β‐actin | 5’‐CCAACCGCGAGAAGATGA‐3’ |
| 5’‐CCAGAGGCGTACAGGGATAG‐3’ |
Abbreviations: FFA, fatty acid synthase; GCase, β‐glucocerebrosidase; PPAR, peroxisome proliferator‐activated receptor; SCD, stearoyl‐CoA desaturase; SREBP, sterol regulatory element‐binding protein.
Figure 1PLS‐DA score plot of skin surface lipid (SSL) for SPSS and NS women. The separation between groups is higher for the samples marked in the black circles, representing a significant difference in lipid information between SPSS and NS women. The separation between the samples labeled in the red circles is lower, representing nonsignificant differences between SPSS and NS women. NS, nonsensitive; PLS‐DA, partial least squares discriminant analysis; SPSS, self‐perceived skin sensitivity.
Figure 2Verification of grouping rationality. (A) Five samples were selected from both NS1 and NS2 for grouping, which showed obvious separation between NS1 (red squares) and NS2 (black squares). (B) The remaining samples in each of the two groups were set as new groups (blue and red squares) to join the first two groups (green and black squares) for analysis, which shows that samples within the same group can be separated. (C) Five samples were selected from each group of SS1 and SS2 for grouping, which showed obvious separation between SS1 (red squares) and SS2 (black squares). (D) The remaining samples in each of the two groups were set as new groups (blue and red squares) to join the first two groups (green and black squares) for analysis, which shows that samples within the same group can be separated. NS1, very insensitive group; NS2, insensitive group; SS1, mildly sensitive group; SS2, severely sensitive group.
Figure 3Scores of lipid differences between samples from NS1 and SS2 groups. Results show obvious separation between SS2 (red squares) and NS1 (black squares) women. NS1, very insensitive group; NS2, insensitive group; SS1, mildly sensitive group; SS2, severely sensitive group.
Information on potential lipid markers between the NS1 and SS groups
| Description | Formula |
| Retention time (min) | Highest mean | Lipid type |
|---|---|---|---|---|---|
| Cer(d18:1/26:1(17Z)) | C44H85NO3 | 676.65 | 10.91 | NS1 | Cer |
| Cer(d18:0/h26:0) | C44H89NO4 | 696.68 | 11.96 | ||
| Cer(d18:0/h24:0) | C42H85NO4 | 668.65 | 10.96 | ||
| PC(4:0/18:1) | C30H58NO8P | 614.39 | 0.54 | GP | |
| PA(13:0/15:0) | C31H61O8P | 593.42 | 6.23 | ||
| PA(17:0/19:0) | C39H77O8P | 705.54 | 11.51 | ||
| PA(12:0/18:0) | C33H65O8P | 621.45 | 7.99 | ||
| Ceriporic acid B | C21H38O4 | 355.28 | 3.93 | FFA | |
| 5‐amino‐pentanoic acid | C5H11NO2 | 118.09 | 0.55 | SS2 | |
| DG(14:1/20:1/0:0) | C37H68O5 | 592.51 | 615.49 | DG | |
| DG(12:0/18:0/0:0) | C33H64O5 | 563.46 | 7.38 |
Abbreviations: DG, diacylglycerol; FFA, free fatty acid; GP, glycerophospholipid; NS1, very insensitive group; PA, phosphatidic acid; PC, phosphatidylcholine; SS2, severely sensitive group.
Details of 62 potential lipid markers
| Group description | NS1 | NS1 | NS1 | NS2 | NS2 | SS1 | Repetition frequency |
|---|---|---|---|---|---|---|---|
| NS2 | SS1 | SS2 | SS1 | SS2 | SS2 | ||
| Cer(d18:0/h24:0) | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| 9R,10S‐epoxy‐stearic acid | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| PA(12:0/18:0) | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| GlcCer(d18:1/16:0) | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| TG(19:1(9Z)/22:0/22:1(11Z))[iso6] | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| PE(15:1(9Z)/12:0) | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| DG(17:2(9Z,12Z)/21:0/0:0)[iso2] | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| PA(O‐16:0/15:0) | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| 11‐keto palmitic acid | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| 11‐methoxy‐12,13‐epoxy‐9‐octadecenoic acid | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| PS(20:5(5Z,8Z,11Z,14Z,17Z)/13:0) | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| PE(14:1(9Z)/12:0) | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| PA(12:0/12:0) | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/21:0) | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| PC(P‐18:1(9Z)/0:0) | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| PE(O‐20:0/22:4(7Z,10Z,13Z,16Z)) | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| DG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/0:0)[iso2] | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| TG(17:1(9Z)/21:0/21:0)[iso3] | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| TG(20:2(11Z,14Z)/22:0/22:0)[iso3] | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| TG(21:0/22:0/22:2(13Z,16Z))[iso6] | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Type IV cyanolipid eicosanoyl ester | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Ceriporic acid A | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Cer(d18:1/26:1(17Z)) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Cer(d18:0/h26:0) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| DG(14:1/20:1/0:0) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| DG(12:0/18:0/0:0) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| PC(4:0/18:1) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| PA(13:0/15:0) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| PA(17:0/19:0) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| 5‐amino‐pentanoic acid | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Ceriporic acid B | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| PE(17:2(9Z,12Z)/18:0) | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| DG(16:1(9Z)/22:0/0:0)[iso2] | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| DG(15:1(9Z)/21:0/0:0)[iso2] | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Phthioceranic acid (C45) | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Docosanedioic acid | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| PI(O‐18:0/12:0) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| PE‐NMe(O‐14:0/O‐14:0) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| DG(16:0/22:0/0:0)[iso2] | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Eicosanedioic acid | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| N‐docosahexaenoyl histidine | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| PG(O‐18:0/16:0) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| PA(17:2(9Z,12Z)/12:0) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
|
1‐(14‐methyl‐pentadecanoyl)−2‐ (8‐[3]‐ladderane‐octanyl)‐sn‐glycerol | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cer(d18:2/23:0) | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 9E,11Z‐Pentadecadienal | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cer(d18:0/16:0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Cer(d18:0/14:0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Cer(d18:1/24:1(15Z)) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| TG(18:1(9Z)/22:0/22:1(13Z))[iso6] | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| TG(19:1(9Z)/20:0/22:1(11Z))[iso6] | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PC(21:4(6Z,9Z,12Z,15Z)/0:0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/ 22:4(7Z,10Z,13Z,16Z)) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PS(P‐18:0/19:1(9Z)) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PE(O‐18:0/O‐18:0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PI(22:2(13Z,16Z)/20:1(11Z)) | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| N‐stearoyl proline | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 17‐methyl‐nonadecanoic acid | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| cis‐cetoleic acid | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| N‐(2’‐(4‐benzenesulfonamide)‐ethyl) arachidonoyl amine | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Sum | 5 | 14 | 11 | 8 | 14 | 18 | — |
Abbreviations: Cer, ceramide; DG, diacylglycerol; GP, glycerophospholipid; NS1, very insensitive group; NS2, insensitive group; PA, phosphatidic acid; PC, phosphatidylcholine; SS1, mildly sensitive group; SS2, severely sensitive group; TG, triglycerid; PE, phosphatidyl ethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine.
Details of lipid standards
| Chemical formula | Structural formula | Biological function |
|---|---|---|
| GlcCer(d18:1/16:0) |
| Precursors synthesized by Cer |
| Cer(d18:0/16:0) |
| The component of sebum to maintain the stability of skin barrier function |
Abbreviations: Cer, ceramide; GlcCer, glucosylceramide.
Figure 4Detection of cell survival rate using a CCK‐8 assay. (A) A gradient of SDS was applied to HaCaT cells for 24 h and a CCK‐8 assay was performed to obtain the absorbance values at 450 nm as a function of SDS concentration. (B) A gradient of Cer was applied to HaCaT cells for 24 h and a CCK‐8 assay was performed to obtain the absorbance values at 450 nm as a function of Cer concentration. (C) A gradient of GlcCer was applied to HaCaT cells for 24 h and a CCK‐8 assay was performed to obtain the absorbance values at 450 nm as a function of GlcCer concentration. CCK‐8, cell counting kit‐8; Cer, ceramide; GlcCer, glucosylceramide; SDS, sodium dodecyl sulfate
Figure 5Curve of the recovery/protective effect of potential lipid markers on barrier‐damaged HaCaT cells as a function of concentration. The results show that Cer and GlcCer have a restorative effect on barrier‐damaged HaCaT cells, but no protective effect. (A) Recovery/protection of barrier‐damaged HaCaT cells by Cer. (B) Recovery/protection of barrier‐damaged HaCaT cells by GlcCer. Cer, ceramide; GlcCer, glucosylceramide
Figure 6Changes in the expression of relevant genes after barrier damage. Results show that the expression of six lipid metabolism‐related genes (SREBP‐1c, FAS, SCD, PPARα, PPARγ, and GCase) is significantly decreased after SDS‐induced cell barrier damage, whereas changes in PPARβ/δ are not significant. FAS, fatty acid synthase; GCase, β‐glucocerebrosidase; PPAR, peroxisome proliferator‐activated receptor; SCD, stearoyl‐CoA desaturase; SDS, sodium dodecyl sulfate; SREBP, sterol regulatory element‐binding protein. **p < 0.01 and *p < 0.05.
Figure 7Relative expression of lipid metabolism‐related genes in barrier‐damaged HaCaT cells after repair by Cer/GlcCer. (A) Effect of Cer on the SREBP‐1c pathway. (B) Effect of GlcCer on the SREBP‐1c pathway. (C) Effect of Cer on the PPAR pathway. (D) Effect of GlcCer on the PPAR pathway. Cer, ceramide; GlcCer, glucosylceramide; PPAR, peroxisome proliferator‐activated receptor; SDS, sodium dodecyl sulfate; SREBP, sterol regulatory element‐binding protein. **p < 0.01 and *p < 0.05.